Eupraxia Pharmaceuticals Inc.

Contributing Author

Recent Articles by Eupraxia Pharmaceuticals Inc.

Oct-09	Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences EPRX GlobeNewswire
Sep-30	Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis EPRX +9.57% GlobeNewswire
Sep-08	Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences EPRX GlobeNewswire
Aug-13	Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients EPRX GlobeNewswire
Aug-11	Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results EPRX GlobeNewswire
Jul-13	Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth EPRX GlobeNewswire
Jul-07	Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization EPRX GlobeNewswire
Jun-19	Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders EPRX GlobeNewswire
May-28	Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference EPRX GlobeNewswire
May-12	Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results EPRX GlobeNewswire
May-06	Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week EPRX GlobeNewswire
May-05	Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) EPRX GlobeNewswire
May-01	Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer EPRX EPRX -5.96% GlobeNewswire
Apr-22	Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting EPRX GlobeNewswire
Apr-21	Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis EPRX GlobeNewswire
Apr-13	Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences EPRX GlobeNewswire
Mar-17	Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis EPRX GlobeNewswire
Mar-12	Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results EPRX GlobeNewswire
Feb-20	Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option EPRX GlobeNewswire
Feb-19	Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants EPRX GlobeNewswire
Feb-18	Eupraxia Pharmaceuticals Announces Proposed Public Offering EPRX GlobeNewswire
Jan-08	Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy EPRX +19.14% GlobeNewswire
Nov-13	Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI EPRX GlobeNewswire
Nov-04	Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results EPRX -10.51% GlobeNewswire
Sep-29	Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs EPRX GlobeNewswire
Sep-24	Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option EPRX GlobeNewswire
Sep-22	Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares EPRX -14.89% GlobeNewswire
Sep-22	Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares EPRX +11.58% EPRX -14.89% GlobeNewswire
Sep-02	First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI EPRX GlobeNewswire
Aug-12	Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update EPRX GlobeNewswire
Jul-22	Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences EPRX GlobeNewswire
Jul-08	Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis EPRX GlobeNewswire
Jun-02	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders EPRX GlobeNewswire
May-07	Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 EPRX -6.77% GlobeNewswire
May-06	Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results EPRX GlobeNewswire
May-05	Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI EPRX GlobeNewswire

Eupraxia Pharmaceuticals Inc.

Recent Articles by Eupraxia Pharmaceuticals Inc.

Upgrade your Finviz experience